Consolidated Statements of Income (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Net revenue	$ 172,826	$ 135,702	$ 328,579	$ 262,312
Operating expenses:
Cost of revenue	63,938	42,681	120,653	81,344
Research and development	27,025	32,962	85,221	65,740
Selling, general and administrative	52,944	40,467	116,426	83,653
Total operating expenses	143,907	116,110	322,300	230,737
Income from operations	28,919	19,592	6,279	31,575
Co-promotion income	4,068	2,500	7,818	2,500
Interest expense	(3,704)	(784)	(7,377)	(784)
Other income	605	697	803	759
Income before income taxes	29,888	22,005	7,523	34,050
Provision for income taxes	(11,854)	(8,251)	(1,095)	(12,725)
Net income	18,034	13,754	6,428	21,325
Net loss attributable to non-controlling interest	60	1	93	1
Net income attributable to The Medicines Company	$ 18,094	$ 13,755	$ 6,521	$ 21,326
Basic earnings per common share attributable to The Medicines Company (USD per share)	$ 0.33	$ 0.25	$ 0.12	$ 0.39
Diluted earnings per common share attributable to The Medicines Company (USD per share)	$ 0.30	$ 0.25	$ 0.11	$ 0.38
Weighted average number of common shares outstanding:
Basic (shares)	55,553	54,035	54,804	54,036
Diluted (shares)	60,261	55,556	59,154	55,614